Optimer Sees Safety, Efficacy Results in Phase III Diarrhea Trial

A Phase III trial for Optimer Pharmaceuticals’ Prulifloxacin demonstrated that the drug is effective and safe for the treatment of infectious diarrhea.

Prulifloxacin is a once-daily oral therapy intended for use over a three-day period. Conducted in Mexico and Peru, the double-blind study met the primary endpoint for the drug’s safety and efficacy as compared with placebo, according to Optimer.

Infectious diarrhea can be caused by infection through bacteria, viruses or parasites after consuming contaminated water or food.